Moreover, the authors showed that ANGPTL2 is upregulated in human prostate cancer tissues after neoadjuvant hormonal therapy and this result suggests its clinical relevance in the hormone refractory mechanisms of prostate cancer. This evidence concerns the gene ANGPTL2 and Familial prostate cancer.